GonarthrosisRAGOCONCT04424628
Radiotherapy 3 vs 6 Gy in Gonarthrosis and Coxarthrosis
A study testing Low dose radiotherapy A and Low dose radiotherapy B in people with Gonarthrosis and Coxarthrosis, run by Fundacion GenesisCare at 1 site in Spain.
Trial summary
This is a non-inferiority study in which the investigators compare two low-dose radiotherapy schemes, which are recommended from DEGRO Clinical Practice Guidelines (3 Gy vs 6 Gy) for the treatment of osteoarthritis and other osteodegenerative disorders. Read more about this study
- Who is it for?
- Ages 50 years and older
- Conditions the study is for
- Gonarthrosis, Coxarthrosis
- What is being tested?
- Low dose radiotherapy A and Low dose radiotherapy B
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 338 participants
- Where
- 1 siteSpain
- Study dates
- 1 May 2019to 30 Apr 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age >50 years
- Gonarthrosis or/and Coxarthrosis diagnose
- At least 1 year of evolution
- Non response to drug or surgery treatments
- Risk of colateral side effects due to the comorbidity of the patient with conventional treatments.
Who cannot join
- Previous high dose radiotherapy in the same location
- Conective tissue disease (LUPUS, reumathoid artritis, esclerodermia, Sd. Raynaud, Sd. Sjögren, polymiositis)
- Inherited Hipersesitivity Sindromes (ataxia-telangiectasia, Fanconi's anaemya, Sd. Nijmegen, Sd. Gorlyn, Sd. Cockayne, Sd. Down, Sd. Gardner, Sd. Usher)
- No follow up possibility
- Other study inclusion
Trial locations and contacts
1 site in 1 country.
Spain1 site, 1 recruiting
- Recruiting
GenesisCare Malaga
Málaga, 29018
Daniel Rivas Sanchez, MD, +34951569589, daniel.rivas@genesiscare.es
Raul Hernanz, MD, +34915644383, raul.hernanz@genesiscare.es
About this study
Official title: Three vs Six Gy in Gonarthrosis and Coxarthrosis. Non Inferiority Study
This is a non-inferiority study in which the investigators compare two low-dose radiotherapy schemes, which are recommended from DEGRO Clinical Practice Guidelines (3 Gy vs 6 Gy) for the treatment of osteoarthritis and other osteodegenerative disorders.
A first randomization will be carried out among the patients included in the study:
Read more
- Patients in arm A will be treated at 3 Gy (0.5 Gy/fraction, 3 fractions/week), and patients in arm B will be treated at 6 Gy (1 Gy/fraction, 3 fractions/week).
- Patients should not know the arm to which they have been randomized.
- Once the treatment is finished, patients will be assessed at 8 weeks. If pain does not improve, a re-irradiation will be performed. If the patients were treated with 3 Gy a new randomization will be performed (3 vs 6 Gy again). If the patiens were treated with 6 Gy they will be re-irradiated with 6 Gy again.
The investigators will analyze the results obtained depending on the dose received and depending on the location of the treatment.
Read the detailed description
Painfull skeletal disorders are susceptible to be treated with low-dose radiotherapy. DEGRO guidelines recommend a dose between 3 and 6 Gy at 0'5 Gy/fraction or 1 Gy/fraction respectively. The investigators want to verify that both treatments (3 and 6 Gy) are similar to improve the pain and function in patiens with gonarthrosis and coxarthrosis, and there are no differences between both treatments, therefore, 3 Gy is not less than 6 Gy.
In this context, a prospective multicenter study is proposed. The study will include 338 patients to assess the efficacy of low dose irradiation (3 vs 6 Gy) in gonarthrosis and coxarthrosis.
- Conditions
- Gonarthrosis, Coxarthrosis
- Being tested
- Low dose radiotherapy A, Low dose radiotherapy B
- Keywords
- Low Dose Radiotherapy, Anti-inflammatory effects, Pain release, Quality of Life
- Medical subject headings
- Osteoarthritis, Knee, Osteoarthritis, Hip
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low dose radiotherapy ARadiation
Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is randomized to 3 or 6 Gy again
Low dose radiotherapy BRadiation
Low dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is treated with 6 Gy again
| Study group | Role | What they receive |
|---|---|---|
| Radiotherapy 3 Gy | Active comparator | Patiens will receive low dose gonarthrosis or coxarthrosis radiotherapy (0.5 Gy in 6 fractions alternating days).
Evaluation of pain releave and quality of live in 8-12 weeks If no effect the patient will be randomized to 3 or 6 Gy again Receives: Radiation: Low dose radiotherapy A |
| Radiotherapy 6 Gy | Active comparator | Patiens will receive low dose gonarthrosis or coxarthrosis radiotherapy (1 Gy in 6 fractions alternating days).
Evaluation of pain releave and quality of live in 8-12 weeks If no effect the patient will be treated with 6 Gy again Receives: Radiation: Low dose radiotherapy B |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain control at 8-12 weeks and every 6 months
To evaluate the non inferiority efficacy of low dose radiotherapy 3 or 6 Gy to change in pain with VAS (Visual Analogue Scale). The patient scores his painfrom 0 (no hurt) to 10 (hurts worst). It is better a low score.
Measured: At 8-12 weeks, 6 months, 12 months, 18 months and 24 months
Quality of Life at 8-12 weeks and every 6 months
To evaluate the non inferiority efficacy of low dose radiotherapy 3 or 6 Gy to change in pain with WOMAC scale (Western Ontario MacMaster Questionnaire). This questionnaire has 24 questions about pain, joint stiffness and joint function. It is better a low score.
Measured: At 8-12 weeks, 6 months, 12 months, 18 months and 24 months
Secondary outcomes (1)
Skin toxicity at 8-12 weeks.
Skin toxicity will be assessed and rated acording to the RTOG scale (0= no change over baseline; 1: Follicular, faint or dull erythema epilation, dry desquamation, decreased sweating; 2: Tender or bright erythema, patchy moist desquamation, moderate oedema; 3: Confluent, moist desquamation other tan skin folds, pitting oedema; 4: Ulceration haemorrhege, necrosis.
Measured: At 8-12 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2020
- Study start1 May 2019
- Primary completion30 Apr 2021 (estimated)
- Study completion30 Apr 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (24)Papers the sponsor has linked to this study.
- Other trials for GonarthrosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Arm 1: 3 Gy (repeated at 8 weeks if necessary. New ramdomization to 3 Gy or 6 Gy) Arm 2: 6 Gy (repeated at 8 weeks if necessry)
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 338 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fundacion GenesisCare
- Sponsor type
- Research network
- Collaborators
- Elekta Limited
- Responsible party
- Sponsor
- Investigators
- Daniel Rivas Sanchez, MD, Principal investigator, Fundacion GenesisCare
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04424628
- Sponsor's protocol ID
- GEN-RAD-2019-01
- Acronym
- RAGOCO
- Status last verified
- Jun 2020
- First submitted
- 1 Jun 2020
- Last updated
- 22 Jun 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The overall results of any research conducted Will be available on study data publication Supportin information: Study protocol Informed Consent Form (ICF)
Publications
Micke O, Seegenschmiedt MH; German Working Group on Radiotherapy in Germany. Consensus guidelines for radiation therapy of benign diseases: a multicenter approach in Germany. Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):496-513. doi: 10.1016/s0360-3016(01)01814-4.
PubMed 11872298Montero Luis A, Hernanz de Lucas R, Hervas Moron A, Fernandez Lizarbe E, Sancho Garcia S, Vallejo Ocana C, Polo Rubio A, Ramos Aguerri A. Radiation therapy for the treatment of benign vascular, skeletal and soft tissue diseases. Clin Transl Oncol. 2008 Jun;10(6):334-46. doi: 10.1007/s12094-008-0209-6.
PubMed 18558580Reichl B, Block A, Schafer U, Bert C, Muller R, Jung H, Rodel F; German Cooperative Group on Radiotherapy for Benign Diseases (GCG-BD). DEGRO practical guidelines for radiotherapy of non-malignant disorders: Part I: physical principles, radiobiological mechanisms, and radiogenic risk. Strahlenther Onkol. 2015 Sep;191(9):701-9. doi: 10.1007/s00066-015-0865-8. Epub 2015 Jun 28.
PubMed 26117368Smith-Bindman R, Lipson J, Marcus R, Kim KP, Mahesh M, Gould R, Berrington de Gonzalez A, Miglioretti DL. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009 Dec 14;169(22):2078-86. doi: 10.1001/archinternmed.2009.427.
PubMed 20008690Jansen JT, Broerse JJ, Zoetelief J, Klein C, Seegenschmiedt HM. Estimation of the carcinogenic risk of radiotherapy of benign diseases from shoulder to heel. Radiother Oncol. 2005 Sep;76(3):270-7. doi: 10.1016/j.radonc.2005.06.034.
PubMed 16157402Minten MJM, Leseman-Hoogenboom MM, Kloppenburg M, Kortekaas MC, Leer JW, Poortmans PMP, van den Hoogen FHJ, den Broeder AA, van den Ende CHM. Lack of beneficial effects of low-dose radiation therapy on hand osteoarthritis symptoms and inflammation: a randomised, blinded, sham-controlled trial. Osteoarthritis Cartilage. 2018 Oct;26(10):1283-1290. doi: 10.1016/j.joca.2018.06.010. Epub 2018 Jul 7.
PubMed 30231990Arenas M, Sabater S, Hernandez V, Rovirosa A, Lara PC, Biete A, Panes J. Anti-inflammatory effects of low-dose radiotherapy. Indications, dose, and radiobiological mechanisms involved. Strahlenther Onkol. 2012 Nov;188(11):975-81. doi: 10.1007/s00066-012-0170-8. Epub 2012 Aug 22.
PubMed 22907572Kern PM, Keilholz L, Forster C, Hallmann R, Herrmann M, Seegenschmiedt MH. Low-dose radiotherapy selectively reduces adhesion of peripheral blood mononuclear cells to endothelium in vitro. Radiother Oncol. 2000 Mar;54(3):273-82. doi: 10.1016/s0167-8140(00)00141-9.
PubMed 10738086Hildebrandt G, Seed MP, Freemantle CN, Alam CA, Colville-Nash PR, Trott KR. Mechanisms of the anti-inflammatory activity of low-dose radiation therapy. Int J Radiat Biol. 1998 Sep;74(3):367-78. doi: 10.1080/095530098141500.
PubMed 9737539Leer JW, van Houtte P, Davelaar J. Indications and treatment schedules for irradiation of benign diseases: a survey. Radiother Oncol. 1998 Sep;48(3):249-57. doi: 10.1016/s0167-8140(98)00051-6.
PubMed 9925244Ott OJ, Niewald M, Weitmann HD, Jacob I, Adamietz IA, Schaefer U, Keilholz L, Heyd R, Muecke R; German Cooperative Group on Radiotherapy for Benign Diseases (GCG-BD). DEGRO guidelines for the radiotherapy of non-malignant disorders. Part II: Painful degenerative skeletal disorders. Strahlenther Onkol. 2015 Jan;191(1):1-6. doi: 10.1007/s00066-014-0757-3. Epub 2014 Sep 20.
PubMed 25238992Seegenschmiedt MH, Katalinic A, Makoski H, Haase W, Gademann G, Hassenstein E. Radiation therapy for benign diseases: patterns of care study in Germany. Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):195-202. doi: 10.1016/s0360-3016(99)00537-4.
PubMed 10758324Leer JW, van Houtte P, Seegenschmiedt H. Radiotherapy of non-malignant disorders: where do we stand? Radiother Oncol. 2007 May;83(2):175-7. doi: 10.1016/j.radonc.2007.04.008. Epub 2007 May 8.
PubMed 17490769Seegenschmiedt MH. New future for radiation therapy of non-malignant diseases? Radiother Oncol. 2005 Jan;74(1):1-2. doi: 10.1016/j.radonc.2005.01.001. No abstract available.
PubMed 15683660Micke O, Ugrak E, Bartmann S, Adamietz IA, Schaefer U, Bueker R, Kisters K, Heinrich Seegenschmiedt M, Fakhrian K, Muecke R. Radiotherapy for calcaneodynia, achillodynia, painful gonarthrosis, bursitis trochanterica, and painful shoulder syndrome - Early and late results of a prospective clinical quality assessment. Radiat Oncol. 2018 Apr 19;13(1):71. doi: 10.1186/s13014-018-1025-y.
PubMed 29673383
Study at a glance
From the registry record, last updated by the sponsor on 22 Jun 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Three vs Six Gy in Gonarthrosis and Coxarthrosis. Non Inferiority Study
- ClinicalTrials.gov ID
- NCT04424628
- Acronym / sponsor ID
- RAGOCO / GEN-RAD-2019-01
- Conditions
- Gonarthrosis, Coxarthrosis
- Keywords
- Low Dose Radiotherapy, Anti-inflammatory effects, Pain release, Quality of Life
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 338 participants (estimated)
- Lead sponsor
- Fundacion GenesisCareResearch network
- Collaborators
- Elekta Limited
- Study start
- 1 May 2019 (actual)
- Primary completion
- 30 Apr 2021 (estimated)
- Study completion
- 30 Apr 2023 (estimated)
- First posted
- 11 Jun 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a non-inferiority study in which the investigators compare two low-dose radiotherapy schemes, which are recommended from DEGRO Clinical Practice Guidelines (3 Gy vs 6 Gy) for the treatment of osteoarthritis and other osteodegenerative disorders.
A first randomization will be carried out among the patients included in the study:
- Patients in arm A will be treated at 3 Gy (0.5 Gy/fraction, 3 fractions/week), and patients in arm B will be treated at 6 Gy (1 Gy/fraction, 3 fractions/week).
- Patients should not know the arm to which they have been randomized.
- Once the treatment is finished, patients will be assessed at 8 weeks. If pain does not improve, a re-irradiation will be performed. If the patients were treated with 3 Gy a new randomization will be performed (3 vs 6 Gy again). If the patiens were treated with 6 Gy they will be re-irradiated with 6 Gy again.
The investigators will analyze the results obtained depending on the dose received and depending on the location of the treatment.
Detailed description
Painfull skeletal disorders are susceptible to be treated with low-dose radiotherapy. DEGRO guidelines recommend a dose between 3 and 6 Gy at 0'5 Gy/fraction or 1 Gy/fraction respectively. The investigators want to verify that both treatments (3 and 6 Gy) are similar to improve the pain and function in patiens with gonarthrosis and coxarthrosis, and there are no differences between both treatments, therefore, 3 Gy is not less than 6 Gy.
In this context, a prospective multicenter study is proposed. The study will include 338 patients to assess the efficacy of low dose irradiation (3 vs 6 Gy) in gonarthrosis and coxarthrosis.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- Arm 1: 3 Gy (repeated at 8 weeks if necessary. New ramdomization to 3 Gy or 6 Gy) Arm 2: 6 Gy (repeated at 8 weeks if necessry)
| Arm | Type | Receives |
|---|---|---|
| Radiotherapy 3 Gy | Active comparator | Radiation: Low dose radiotherapy APatiens will receive low dose gonarthrosis or coxarthrosis radiotherapy (0.5 Gy in 6 fractions alternating days). Evaluation of pain releave and quality of live in 8-12 weeks If no effect the patient will be randomized to 3 or 6 Gy again |
| Radiotherapy 6 Gy | Active comparator | Radiation: Low dose radiotherapy BPatiens will receive low dose gonarthrosis or coxarthrosis radiotherapy (1 Gy in 6 fractions alternating days). Evaluation of pain releave and quality of live in 8-12 weeks If no effect the patient will be treated with 6 Gy again |
Who may qualify
- Ages
- 50 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age >50 years
- Gonarthrosis or/and Coxarthrosis diagnose
- At least 1 year of evolution
- Non response to drug or surgery treatments
- Risk of colateral side effects due to the comorbidity of the patient with conventional treatments.
Key exclusion criteria (5 listed)
- Previous high dose radiotherapy in the same location
- Conective tissue disease (LUPUS, reumathoid artritis, esclerodermia, Sd. Raynaud, Sd. Sjögren, polymiositis)
- Inherited Hipersesitivity Sindromes (ataxia-telangiectasia, Fanconi's anaemya, Sd. Nijmegen, Sd. Gorlyn, Sd. Cockayne, Sd. Down, Sd. Gardner, Sd. Usher)
- No follow up possibility
- Other study inclusion
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low dose radiotherapy ALow dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is randomized to 3 or 6 Gy again | Radiation | Radiotherapy 3 Gy |
| Low dose radiotherapy BLow dose radiotherapy was 0.5 Gy in 6 fractions. Evaluation of pain and Quality of Life in 8-12 weeks. If no pain releave the patient is treated with 6 Gy again | Radiation | Radiotherapy 6 Gy |
Primary outcome
Pain control at 8-12 weeks and every 6 months
Time frame: At 8-12 weeks, 6 months, 12 months, 18 months and 24 months
To evaluate the non inferiority efficacy of low dose radiotherapy 3 or 6 Gy to change in pain with VAS (Visual Analogue Scale). The patient scores his painfrom 0 (no hurt) to 10 (hurts worst). It is better a low score.
Quality of Life at 8-12 weeks and every 6 months
Time frame: At 8-12 weeks, 6 months, 12 months, 18 months and 24 months
To evaluate the non inferiority efficacy of low dose radiotherapy 3 or 6 Gy to change in pain with WOMAC scale (Western Ontario MacMaster Questionnaire). This questionnaire has 24 questions about pain, joint stiffness and joint function. It is better a low score.
1 secondary outcome
Skin toxicity at 8-12 weeks.
Time frame: At 8-12 weeks.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jun 2020.
- Background: PubMed 11872298Micke O, Seegenschmiedt MH; German Working Group on Radiotherapy in Germany. Consensus guidelines for radiation therapy of benign diseases: a multicenter approach in Germany. Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):496-513. doi: 10.1016/s0360-3016(01)01814-4.
- Background: PubMed 18558580Montero Luis A, Hernanz de Lucas R, Hervas Moron A, Fernandez Lizarbe E, Sancho Garcia S, Vallejo Ocana C, Polo Rubio A, Ramos Aguerri A. Radiation therapy for the treatment of benign vascular, skeletal and soft tissue diseases. Clin Transl Oncol. 2008 Jun;10(6):334-46. doi: 10.1007/s12094-008-0209-6.
- Background: PubMed 26117368Reichl B, Block A, Schafer U, Bert C, Muller R, Jung H, Rodel F; German Cooperative Group on Radiotherapy for Benign Diseases (GCG-BD). DEGRO practical guidelines for radiotherapy of non-malignant disorders: Part I: physical principles, radiobiological mechanisms, and radiogenic risk. Strahlenther Onkol. 2015 Sep;191(9):701-9. doi: 10.1007/s00066-015-0865-8. Epub 2015 Jun 28.
- Background: PubMed 20008690Smith-Bindman R, Lipson J, Marcus R, Kim KP, Mahesh M, Gould R, Berrington de Gonzalez A, Miglioretti DL. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009 Dec 14;169(22):2078-86. doi: 10.1001/archinternmed.2009.427.
- Background: PubMed 16157402Jansen JT, Broerse JJ, Zoetelief J, Klein C, Seegenschmiedt HM. Estimation of the carcinogenic risk of radiotherapy of benign diseases from shoulder to heel. Radiother Oncol. 2005 Sep;76(3):270-7. doi: 10.1016/j.radonc.2005.06.034.
- Background: PubMed 30231990Minten MJM, Leseman-Hoogenboom MM, Kloppenburg M, Kortekaas MC, Leer JW, Poortmans PMP, van den Hoogen FHJ, den Broeder AA, van den Ende CHM. Lack of beneficial effects of low-dose radiation therapy on hand osteoarthritis symptoms and inflammation: a randomised, blinded, sham-controlled trial. Osteoarthritis Cartilage. 2018 Oct;26(10):1283-1290. doi: 10.1016/j.joca.2018.06.010. Epub 2018 Jul 7.
- Background: PubMed 22907572Arenas M, Sabater S, Hernandez V, Rovirosa A, Lara PC, Biete A, Panes J. Anti-inflammatory effects of low-dose radiotherapy. Indications, dose, and radiobiological mechanisms involved. Strahlenther Onkol. 2012 Nov;188(11):975-81. doi: 10.1007/s00066-012-0170-8. Epub 2012 Aug 22.
- Background: PubMed 10738086Kern PM, Keilholz L, Forster C, Hallmann R, Herrmann M, Seegenschmiedt MH. Low-dose radiotherapy selectively reduces adhesion of peripheral blood mononuclear cells to endothelium in vitro. Radiother Oncol. 2000 Mar;54(3):273-82. doi: 10.1016/s0167-8140(00)00141-9.
- Background: PubMed 9737539Hildebrandt G, Seed MP, Freemantle CN, Alam CA, Colville-Nash PR, Trott KR. Mechanisms of the anti-inflammatory activity of low-dose radiation therapy. Int J Radiat Biol. 1998 Sep;74(3):367-78. doi: 10.1080/095530098141500.
- Background: PubMed 9925244Leer JW, van Houtte P, Davelaar J. Indications and treatment schedules for irradiation of benign diseases: a survey. Radiother Oncol. 1998 Sep;48(3):249-57. doi: 10.1016/s0167-8140(98)00051-6.
- Results publication: PubMed 25238992Ott OJ, Niewald M, Weitmann HD, Jacob I, Adamietz IA, Schaefer U, Keilholz L, Heyd R, Muecke R; German Cooperative Group on Radiotherapy for Benign Diseases (GCG-BD). DEGRO guidelines for the radiotherapy of non-malignant disorders. Part II: Painful degenerative skeletal disorders. Strahlenther Onkol. 2015 Jan;191(1):1-6. doi: 10.1007/s00066-014-0757-3. Epub 2014 Sep 20.
- Results publication: PubMed 10758324Seegenschmiedt MH, Katalinic A, Makoski H, Haase W, Gademann G, Hassenstein E. Radiation therapy for benign diseases: patterns of care study in Germany. Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):195-202. doi: 10.1016/s0360-3016(99)00537-4.
- Individual participant dataSharing planned: No. The overall results of any research conducted Will be available on study data publication Supportin information: Study protocol Informed Consent Form (ICF)
Related trials for Gonarthrosis
Not yet recruiting
Bipolar Versus Cooled Radiofrequency Ablation for Gonarthrosis
Gonarthrosis
Recruiting
The Effect of Tail Fat Application on Joint Pain, Joint Stiffness, and Daily Living Activities in Patients With Gonarthrosis
Gonarthrosis
Not yet recruiting
US-Guided Saphenous Block in Knee OA
Knee Osteoarthritis, Osteoarthritis, Knee
Active, not recruitingObservational study
Knee Joint Position Sense in Knee Osteoarthritis
Knee Osteoarthritis, Gonarthrosis
RecruitingObservational study
Oral vs Intravenous Dexamethasone in Total Knee Arthroplasty
Knee Osteoarthritis, Gonarthrosis; Primary
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Daniel Rivas Sanchez, MD principal investigator
Fundacion GenesisCare
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low dose radiotherapy A and Low dose radiotherapy B in people with Gonarthrosis and Coxarthrosis, run by Fundacion GenesisCare at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 22 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Daniel Rivas Sanchez, MD (+34951569589, daniel.rivas@genesiscare.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain control at 8-12 weeks and every 6 months (time frame: At 8-12 weeks, 6 months, 12 months, 18 months and 24 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04424628, which also lists 24 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jun 2020.